Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | ABAT | P80404 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 6/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 3/20 | 0.36 |
| ▸ | NOS1 | P29475 | 3/20 | 0.36 |
| ▸ | NOS2 | P35228 | 3/20 | 0.36 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.34 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9973082 | 1.00 | TAAR1 (0.42) | TAAR1ABATPTGS2LOXL2TP53 | |
| SCHEMBL16727658 | 0.92 | RXRA (0.45) | TAAR1ABATPTGS2LOXL2TP53 | |
| SCHEMBL27951798 | 0.92 | TAAR1 (0.37) | TAAR1ABATPTGS2LOXL2TP53 | |
| SCHEMBL19979027 | 0.89 | LOXL2 (0.40) | TAAR1ABATPTGS2LOXL2TP53 | |
| SCHEMBL13981840 | 0.89 | PGK1 (0.37) | TAAR1ABATPTGS2LOXL2NOS3 | |
| SCHEMBL18494541 | 0.87 | IDO1 (0.41) | TAAR1ABATPTGS2LOXL2NOS3 | |
| SCHEMBL27669043 | 0.87 | LOXL2 (0.37) | TAAR1ABATPTGS2LOXL2NOS3 | |
| SCHEMBL10666038 | 0.87 | ABAT (0.48) | TAAR1ABATPTGS2NOS3NOS1 | |
| SCHEMBL24422397 | 0.85 | NOS1 (0.37) | TAAR1ABATPTGS2LOXL2NOS3 | |
| SCHEMBL15249714 | 0.83 | PLG (0.33) | TAAR1ABATPTGS2LOXL2CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130149931-A1 | Multilayer Laminated Articles Including Poly(ureaurethane) Layers and Methods of Making the Same | PPG INDUSTRIES OHIO, INC. (US) | 2013-06-13 | — | — | US | claimed |
| US-11219588-B2 | Use of polyamines in compositions and methods for inducing or promoting skin darkening and regulating melanogenesis | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-01-11 | — | — | US | disclosed |
| WO-2018127699-A1 | COMPOUNDS FOR TREATING CANCER | Bicyclerd Limited (GB) | 2018-07-12 | — | — | WO | disclosed |
| EP-2651876-A1 | POLYAMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS | Sika Technology AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012080265-A1 | POLYAMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS | SIKA TECHNOLOGY AG (CH) | 2012-06-21 | — | — | WO | disclosed |
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-10-06 | — | — | US | disclosed |
| US-20080175914-A1 | Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED | 2008-07-24 | — | — | US | disclosed |
| US-20080175914-A1 | Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED | 2008-07-24 | — | — | US | disclosed |
| EP-0417540-A2 | Masses of reactive polyurethane adhesives comprising finely dispersed polymers | BAYER AG (DE) | 1991-03-20 | — | — | EP | disclosed |
| EP-0150803-A2 | PVC-plastisols for coating applications containing adhesion improving additives and their use | BAYER AG (DE) | 1985-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | TAAR1 783/4885ABAT 372/4885PTGS2 1196/4885 |
| US-20080175914-A1 | Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors | PDE5A, PDE3B, PDE4A | TAAR1 1517/4885ABAT 2578/4885PTGS2 484/4885 |
| US-11219588-B2 | Use of polyamines in compositions and methods for inducing or promoting skin darkening and regulating melanogenesis | TYR, MITF, SRM | TAAR1 1631/4885ABAT 580/4885PTGS2 2266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.